Akribion Therapeutics

• 04/02/2025
• Seed
• $8,275,080

Akribion Therapeutics is developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Its G-dase® E payload has the ability to kill cells by shredding DNA and RNA, but only if there is a highly specific match between the guide RNA and an intracellular RNA sequence, ensuring that only the targeted cells are affected, leaving healthy cells unharmed.

Initially targeting HPV-induced Oropharyngeal Head & Neck Cancer (OPSCC), Akribion is exploring additional applications in oncology, autoimmune diseases, fibrosis, and infectious diseases.

The flexibility and broad potential of Akribion's technology makes it a promising platform for various therapeutic areas, as by simply changing the guide RNA, the technology can be quickly adapted to target different cells, making it much faster to develop new treatments compared to traditional methods.

Founded in 2024 and based in Zwingenberg, Germany, Akribion was spun out of BRAIN Biotech AG, the specialist in biosolutions for industrial applications.

---

---